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Abstract
Purpose The aim of this study is to determine overall surviv-
al, disease-specific survival and stoma-free survival after treat-
ment of squamous cell carcinoma of the anus with chemora-
diotherapy followed by brachytherapy or electron boost in a
recent cohort of patients.
Methods Fifty-two patients (median age 62 years) were treat-
ed with radical chemoradiotherapy (mitomycin C, infusional
5-fluorouracil concurrently with conformal radical radiother-
apy 45 Gy in 25 fractions over 5 weeks) followed by a radio-
therapy boost between 1 December 2000 and 30 April 2011.
Follow-up was to 30 November 2014. Thirty-six patients re-
ceived a boost (15–20 Gy) over 2 days with 192Ir needle
brachytherapy for anal canal tumours, and 16 patients re-
ceived electron beam therapy (20 Gy in 10 fractions in
2 weeks) for anal margin tumours. A defunctioning stoma
was only created prior to chemoradiotherapy for fistula or
severe anal pain.
Results The overall survival for the 36 patients treated with
chemoradiotherapy followed by brachytherapy was 75 %
(95 % CI, 61–89) at 5 years, the disease-specific survival
was 91 % (95 % CI, 81–101 %), and the stoma-free survival
was 97 % (95 % CI, 91–103 %) all at 5 years. For the 16
patients treated with an electron boost for anal margin tu-
mours, the 5-year overall survival, disease-specific survival
and stoma-free survival were 68 % (95 % CI, 44–92 %),
78 % (95 % CI, 56–100 %) and 80 % (95 % CI, 60–100 %),
respectively.
Conclusions Avery low stoma formation rate can be obtained
with radical chemoradiotherapy followed by a brachytherapy
boost for squamous cell carcinoma of the anal canal but not
with an electron boost for anal margin tumours.
Keywords Anal cancer . Stoma formation . Boost .
Brachytherapy . Electron beam therapy . Radiotherapy
Introduction
Squamous cell carcinoma (SCC) of the anus is caused pre-
dominantly (84 %) by human papilloma virus (HPV 16) in
comparison to cervical carcinoma (70 %) (HPV 16 and 18)
and oropharyngeal carcinoma (33 %) (HPV 16) [1]. In con-
trast to the high doses of radical radiotherapy (65–70 Gy) used
in the chemoradiotherapy of cervical carcinoma and oropha-
ryngeal carcinoma, recent trials particularly in the UK ACT II
trial [2] have established that doses of 50.4 Gy in 28 daily
fractions combined with mitomycin C and 5-fluorouracil give
a 3-year progression-free survival of 80 % for T1 or T2 dis-
ease but 65 % for T3 or T4 disease. Similarly, the 3-year
colostomy-free survival was 84 % for T1 or T2 disease and
61 % for patients with T3 or T4 disease. In the RTOG 98-11
trial [3] published in 2008, in which a radiotherapy boost of
10–14 Gy in 2 Gy fractions was given for locally advanced
disease (total 55–59 Gy), the 5-year colostomy-free survival
was 90% in theMitomycin-based group. European guidelines
for diagnosis, treatment, and follow-up of anal cancer have
recently been published [4]. The results of chemoradiotherapy
with brachytherapy or electron therapy boost in Nottingham,
UK (2000–2011), for locally advanced SCC of the anus were
analysed to determine overall survival, disease-specific
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survival and stoma-free survival. The patients were treated
during the modern era with discussion of patients at a multi-
disciplinary team meeting and treatment by a specialist sur-
geon and oncologist.
Methods
All patients referred to Nottingham City Hospital, UK,
between 1 December 2000 and 30 April 2011 for
chemo/radiotherapy for SCC of the anal canal or margin
were identified. No patient was documented with HIV
infection. These patients had all been discussed at the
Colorectal Cancer Multi-disciplinary Team Meetings
(which started in the year 2000) held at Queens Medical
Centre, Nottingham, which included patients with anal
cancer. These patients were recorded on an electronic da-
tabase. All patients gave informed written consent to treat-
ment. The project was considered by the Nottingham
Research Ethics Committee as an audit and hence was ethi-
cally approved as part of a cohort of audits undertaken at the
time by Nottingham University Hospital NHS Trust. An indi-
vidual ethical assessment of this project was not deemed nec-
essary. In addition, ethical approval was obtained from Trent
Cancer Registry to access data on patients with anal cancer.
The lead surgeon, J. Scholefield, and the lead oncologist, E.
Bessell, were responsible for treating the vast majority of these
patients. All the patients were treated using standard depart-
mental protocols (no extra treatments or investigations were
carried out).
The staging investigations were as follows: the local extent
of the anal cancer was determined by digital examination and
proctoscopy. The position of the tumour in the lithotomy po-
sition was recorded with 12 o’clock representing the anterior
position and 6 o’clock representing the posterior position. The
distance from the anal verge was measured and also the length
of the tumour. Magnetic resonance imaging and endorectal
ultrasound examination were not used. All patients had a CT
scan of chest, abdomen and pelvis, and a fine needle aspirate
was obtained from suspicious inguinal lymph nodes for cyto-
logical examination.
No defunctioning stoma was formed unless deemed essen-
tial. Patients were advised to have a low-roughage diet during
treatment.
For each patient, information was obtained on age, sex,
TNM stage, histology, the date of diagnosis and the date of
starting treatment, the chemotherapy used, the radiotherapy
dose both external beam and boost, the use of defunctioning
colostomy and the date of any salvage surgery. The patients
were followed 3-monthly for 2 years and 4–6-monthly until a
minimum of 5 years of follow-up. Local recurrence was
assessed initially by digital examination and confirmed histo-
logically and by magnetic resonance imaging (MRI). Patients
with confirmed local recurrencewere investigated further with
a CT scan of chest, abdomen and pelvis.
Anal function was assessed by Common Terminology
Criteria for Adverse Events (CTCAE) version 4.0.
Early-stage disease was considered to be T1 N0 or T2
(<3 cm in diameter) N0. All other stages were considered to
be locally advanced.
Treatment
Patients with early-stage disease were considered for entry
into the ACT II trial [2] which recruited between
June 2001 and December 2008. Following the closure of
this trial, standard treatment for early-stage disease was
mitomycin/fluorouracil concurrently with external beam
radiotherapy to a total dose of 50.4 Gy in 28 daily frac-
tions over 5.5 weeks.
Patients with locally advanced disease were treated with
mitomycin/fluorouracil according to the protocol of the ACT
I trial [5]. The radiotherapy was also prescribed according to
this protocol. The standard pelvic field was defined with su-
perior border 2 cm above the inferior aspect of the sacroiliac
joints, the inferior border 3 cm below the anal margin or 3 cm
below the inferior extent of the anal tumour. The lateral as-
pects were arranged to cover the inguinal nodes with no rou-
tine shielding of the femoral heads. The mid line dose was
45 Gy in 25 fractions (1.8 Gy per fraction) in 5 weeks with an
anterior-posterior field arrangement.
A radiotherapy boost of 15–20 Gy over 2 days was given
with low dose rate [192]Ir brachytherapy for anal canal tu-
mours. Five needles were used covering the hemicircumference
containing the tumour, sparing the other hemicircumference in
order to preserve sphincter function. A specially designed tem-
plate was used in the majority of patients. A radiotherapy boost
of 20 Gy in ten fractions in 2 weeks was given with high energy
electrons to anal margin tumours.
Statistical Analysis
Overall survival, disease-specific survival and stoma-free sur-
vival were estimated using the Kaplan-Meier method with
IBM SPSS Statistics version 21.
Results
A total of 92 patients were found on the database for the
period 1 December 2000 to 30 April 2011 (see Table 1).
Follow-up was to 30 November 2014. At that date, 50 of the
92 patients were alive without recurrence (median follow-up
7.2 years, range 3–14 years). There was female predominance
as expected with 60 females and 32 males. The seven patients
treated with palliative intent were so treated because of
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advanced age, medical comorbidities or extensive local or
metastatic disease. There were also eight patients not fit
enough for chemotherapy who received radical external beam
radiotherapy (three of these had an iridium boost). Twenty-
five patients received chemoradiotherapy with no boost. This
was a mixed group of patients including those entered into the
ACT II trial or treated by the ACT II radiotherapy protocol,
those refusing a boost often because of a prolonged acute
radiation reaction and those too frail for further treatment.
There were therefore 52 patients receiving radical chemora-
diotherapy with a boost (36 iridium: 16 electron).
Radical Chemoradiotherapy with Iridium Brachytherapy
Boost
The disease-specific survival for these 36 patients (Fig. 1) was
91% (95%CI 81–101) at 5 years with only one local recurrence
and two additional patients developing metastatic disease. One
patient had a defunctioning stoma which was formed prior to
treatment and not reversed. The overall survival was 75% (95%
CI 61–89) at 5 years (Fig. 2). The patient with local recurrence
only had a salvage abdomino-perineal resection with a stoma but
died of disease 15 months later.
Radical Chemoradiotherapy with Electron Boost
The disease-specific survival for these 16 patients (Fig. 1) was
78 % (95 % CI 56–100) at 5 years with two local recurrences
and one additional patient who developed metastatic disease.
Only one patient had a stoma formed before chemoradiother-
apy for a T4 tumour, and this was not reversed.
The overall survival was 68 % (95 % CI 44–92) at 5 years
(Fig. 2). The two patients who developed local recurrence had
salvage abdomino-perineal resection with a stoma but both
died of metastatic disease.
It was not the intention of this retrospective study to com-
pare the survival of patients with anal canal tumours with
those with anal margin tumours, but the log-rank test showed
no statistically significant difference between the electron
boost group and the brachytherapy group as far as disease-
specific survival (p = 0.272) and overall survival (p = 0.375) is
concerned.
Toxicity
The toxicity from chemoradiotherapy for anal cancer is well
documented from the large randomised controlled trials. Only
2 of the 52 patients receiving radical chemoradiotherapy with
Table 1 Demographic characteristics of the patients studied
Whole group, n = 92
Age (median) 59.5 years
Gender: Male 32 (35 %)
Female 60 (65 %)
Treatment intent: Palliative 7 Radical 85
N-stage T-stage No. of patients % of total
N0 T1 19 20.7
N0 T2 37 40.2
N0 T3 20 21.7
N0 T4 6 6.5
N1 T3 1 1.1
N1 T4 4 4.4
N2 T3 3 3.3
N3 T3 1 1.1
N3 T4 1 1.1
Radical treatment
Chemoradiotherapy plus boost, n = 52
Anal canal Anal margin
Iridium boost, n = 36 Electron boost, n = 16
Age (median) 61 years Age (median) 63 years
Stage No. of patients (%) Stage No. of patients (%)
T1 N0 3 (8.3) T1 N0 4 (25)
T2 N0 17 (47.2) T2 N0 7 (43.8)
T3 N0 14 (38.9) T3 N0 2 (12.5)
T2 N2 1 (2.8) – –
T3 N2 1 (2.8) – –
– – T4 N0 2 (12.5)
– – T4 N1 1 (6.2)
Radical treatment (other)
External beam radiotherapy alone 8
Chemoradiotherapy without boost 25
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a boost developed prolonged grade 3 toxicity, and one of these
was later found to be associated with local recurrence.
Anal Function and Stoma Formation
Two of the 52 patients treated with radical chemoradiotherapy
and a boost had a stoma formed before treatment which was
not reversed, and 3 patients had a stoma formed because of
abdomino-perineal resection for local recurrence but died of
disease. There were therefore 47 patients without a stoma. The
stoma-free survival at 5 years was 97 % (95 % CI 91–103)
(Fig. 3) for the 36 patients who received brachytherapy as a
boost and 80 % (95 %, CI 60–100) for the 16 patients who
received electron therapy as a boost. These stomas were all
cancer rather than treatment-related, and therefore, the cancer-
related stoma rates were 3 % at 5 years for the brachytherapy
group and 20 % at 5 years for the electron group. The reasons
for the defunctioning colostomy in the two patients who had a
Fig. 1 Kaplan-Meier plot
showing disease-specific survival
for the groups receiving radical
chemoradiotherapy with either
the iridium boost or electron
boost. The cumulative proportion
surviving at 5 years (95 % CI)
was 0.91 (0.81, 1.01) for the
iridium group and 0.78 (0.56,
1.00) for the group receiving the
electron boost. The log-rank test
showed no statistically significant
difference between the two
groups (p = 0.272)
Fig. 2 Kaplan-Meier plot
showing overall survival for the
groups receiving radical
chemoradiotherapy with either
the iridium boost or electron
boost. The cumulative proportion
surviving at 5 years (95 % CI)
was 0.75 (0.61, 0.89) for the
iridium group and 0.68 (0.44,
0.92) for the group receiving the
electron boost. The log-rank test
showed no statistically significant
difference between the two
groups (p = 0.375)
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stoma formed prior to definitive chemoradiotherapy was in
one, severe anal pain requiring inpatient care with poor control
with analgesics and in the other a rectovaginal fistula.
There were five stomas formed in the mixed group of 25
patients who received chemoradiotherapy without boost. One
patient required a defunctioning colostomy prior to chemora-
diotherapy because of severe anal pain and faecal inconti-
nence. One patient developed a rectovaginal fistula during
chemoradiotherapy causing treatment to be interrupted. One
patient developed a sigmoid stricture after chemoradiotherapy
requiring a Hartmann’s procedure. Two patients received an
abdominoperineal resection of rectum for local recurrence
(one with additional vulvectomy). None of these patients
wished to have a defunctioning stoma because of poor anal
function. All patients were asked about anal function in the
follow-up clinic, and all were satisfied with their anal func-
tion. No formal score such as the Wexner incontinence score
was used [6].
Discussion
The main aims in the treatment of SCC of the anus are to
achieve a high rate of cure without a permanent stoma and
adequate (from the patients perspective) anal function [7]. We
have shown that this is possible to achieve in an unselected
population, but over 20% of our patients seen from this defined
population were not suitable for radical chemotherapy. In order
to achieve these goals, it is important that an initial
defunctioning colostomy is not performed unless there is a
fistula (in particular a recto-vaginal fistula) or distressing anal
pain. In addition, a high enough dose of radiotherapy is needed
for advanced tumours (large T2, T3 and T4) to obtain a high
rate of local control [8, 9]. A brachytherapy boost [10, 11] to a
hemicircumference of the anal canal achieves the higher dose
without giving the full dose to the hemicircumference not im-
planted. This is impossible to achieve by any other method
including intensity modulated radiotherapy [12–16] which is
not cost-effective [17]. A major disadvantage of anal brachy-
therapy in general radiotherapy practise is that relatively few
radiation oncologists are trained in this technique.
In this study, the number of patients treated was small com-
pared to the six published randomised controlled trials [2, 3, 5,
9, 18, 19]. However, there were only three local recurrences
after radical chemoradiotherapy with a brachytherapy or elec-
tron boost in 52 patients, showing that a high rate of local
control can be obtained in patients resident in a defined
population.
Close collaboration between specialist colorectal cancer
surgeons with an interest in anal cancer and oncologists with
a specialist interest in anal cancer at multidisciplinary team
meetings can result in the smallest achievable percentage of
stomas created prior to treatment. It is important that in addi-
tion to reporting permanent colostomy rates, cancer-related
and treatment-related colostomy rates are also reported
[20–24].
A low rate of stoma formation occurred in this study espe-
cially in the brachytherapy group. Only 2 of 52 patients had a
stoma formed prior to treatment because of anal pain or fistula,
and these stomas were not reversed. The three patients with
local recurrence all had salvage abdomino-perineal excision of
rectum performed, and all three had further recurrence. In the
Fig. 3 Kaplan-Meier plot
showing stoma-free survival for
the groups receiving radical
chemoradiotherapy with either
the iridium boost or electron
boost. The cumulative proportion
surviving stoma-free at 5 years
(95 % CI) was 0.97 (0.91, 1.03)
for the iridium group and 0.80
(0.60, 1.00) for the group
receiving the electron boost. The
log-rank test showed no
statistically significant difference
between the two groups
(p = 0.119)
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UNICANCER ACCORD 3 trial [9], patients treated initially
with definitive colostomy were not eligible for the study but a
temporary colostomy was allowed for severe symptoms or
fistula if a reversal of the colostomy was reasonably expected.
The 5-year colostomy-free survival was 73.7–77.8 % in this
trial. All patients in this trial received a boost either with 192Ir
brachytherapy or electron beam therapy. No information was
given concerning reversal of the temporary colostomies. The
colostomy-free survival in this trial was higher than expected
in the standard dose boost with no induction chemotherapy.
The patients were recruited between 1999 and 2005. In our
retrospective study, the patients were treated between 2000
and 2011. It is possible that in our single-centre study, it was
easier to limit the use of a stoma than in a multicentre
randomised trial, and consequently, the cancer-related stoma
rate at 5 years was 3 % for the brachytherapy group and 20 %
for the electron group with no treatment-related stomas at
5 years.
The assessment of anal function however during the
follow-up of patients is difficult for several reasons:
1. The estimated prevalence of anal incontinence (including
double incontinence) in the normal population (excluding
people in care homes) over the age of 65 years is 5–10 %
in men and 10–15 % in women [6, 25].
2. Themajor cause of damage to the anal canal and sphincter
is probably caused by the anal cancer and may wholly or
partly be permanent.
3. Unless there is considerable fibrosis after treatment, it
may be difficult to attribute poor anal function to the effect
of treatment.
4. Patients find discussing anal incontinence embarrassing
and may play-down their symptoms. In this study, all
the patients without a stoma or local recurrence were sat-
isfied with their anal function.
Conclusions
A low rate of stoma formation can be achieved in the treat-
ment of anal cancer with chemoradiotherapy if the number of
stomas prior to treatment is kept to a minimum and the treat-
ment protocol used leads to a low rate of local recurrence. The
indication in our series for a stoma prior to chemoradiotherapy
was either severe anal pain with or without faecal incontinence
or a rectovaginal fistula. In all other patients, a stoma prior to
chemoradiotherapy was avoided.
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